All In Biotech

Drug Trial Radar · NCT05305573

Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.

A Phase IIb, Double-Blind, Randomized, Active Controlled, Multi-center, Non-inferiority Trial to Assess Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Fusion Dimer Candidate (PHH-1V) Against SARS-CoV-2, in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Mar 25, 2022

Primary completion

Nov 14, 2023

Study completion Nov 14, 2023

Sponsor

Lead sponsor
Hipra Scientific, S.L.UIndustry
Sponsor type
Industry
First posted
Mar 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase IIb clinical trial to assess the Immunogenicity and Safety of a HIPRA's Candidate Booster vaccination (PHH-1V) in adults fully vaccinated with the adenovirus vaccine Vaxevria against COVID-19.

Conditions

  • SARS-CoV-2 Infection

Interventions

  • COVID-19 Vaccine HIPRA 40 ug/doseBiological

    Subjects will receive one injection of COVID-19 Vaccine HIPRA (PHH-1V)

  • Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injectionBiological

    Subjects will receive one injection of Comirnaty Vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes of the immunogenicity against Omicron strain at Day 14Time frame: Day 14
  2. Safety and tolerability of PHH-1V as a booster doseTime frame: Day 7
  3. Safety and tolerability of PHH-1V as a booster doseTime frame: Day 28
  4. Safety and tolerability of PHH-1V as a booster doseTime frame: Day 182
  5. Safety and tolerability of PHH-1V as a booster doseTime frame: Day 182
  6. Safety and tolerability of PHH-1V as a booster doseTime frame: Day 182
  7. Safety and tolerability of PHH-1V as a booster doseTime frame: Days 14, 98 and 182

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital HM Modelo

    A Coruña, Spain

  • Hospital Gregorio Marañón

    Madrid, Spain

  • Hospital HM Sanchinarro

    Madrid, Spain

  • Hospital HM Puerta del Sur

    Móstoles, Spain

  • Complejo Hospitalario Universitario de Santiago

    Santiago de Compostela, Spain

  • Hospital HM Rosaleda

    Santiago de Compostela, Spain

  • Complejo Hospitalario Universitario de Vigo

    Vigo, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.